Bristol Myers Squibb stock holds as investors await fresh earnings cues
Published on 08/11/2026 at 14:36 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Bristol Myers Squibb (US0897961004) is framed by its latest full-year outlook, which points to 2026 revenue of $46.5 billion to $47.5 billion and non-GAAP EPS of $6.70 to $7.00. The company also reported 2025 revenue of $48.3 billion and adjusted EPS of $8.39, giving investors a clear comparison base.
2026 guidance still sets the tone
The 2026 revenue range implies a step down from 2025, while the EPS range remains below the prior year adjusted result. That contrast matters because Bristol Myers Squibb stock is being valued against a business that still generates large-scale cash flows, but with a 2026 top-line reset that is visible in the numbers.
Management also guided to adjusted cost of products sold as a percentage of revenue of about 15%, research and development expense of about $11.0 billion, and marketing, selling and administrative expense of about $7.5 billion for 2026. Those figures help explain where margin pressure and investment intensity are expected to land in the new fiscal year.
Cash flow and capital returns
Bristol Myers Squibb generated $15.8 billion in operating cash flow in 2025, according to its latest investor materials, and returned $11.7 billion to shareholders through dividends and share repurchases. That combination shows why the stock can still draw income-oriented investors even as earnings expectations reset.
The company ended 2025 with cash, cash equivalents and marketable securities of $12.9 billion, alongside total debt of $49.6 billion. For the market, that balance-sheet mix is part of the valuation debate because refinancing, flexibility and payout capacity all sit in the same frame.
Product mix matters
Eliquis remained the biggest product contributor in the latest reported year, with 2025 revenue of $13.4 billion. That single product still carries heavy weight for Bristol Myers Squibb stock, because changes in the product mix can move the earnings profile faster than the headline revenue line suggests.
Opdivo brought in $9.3 billion in 2025 revenue, while the combined hematology and oncology portfolio stayed central to the companys earnings base. The product concentration means investors continue to watch the franchise mix, not just the consolidated guidance range.
Price context from the last close
The shares closed at $47.12 on the latest available market day, leaving the stock tied to a valuation debate that is anchored more in earnings quality than in near-term growth. At that level, the market is still weighing the 2026 guidance against the 2025 cash generation profile and the durability of the dividend and buyback mix.
Bristol Myers Squibb at a glance
- Company: Bristol Myers Squibb Company
- ISIN: US0897961004
- Ticker: NYSE: BMY
- Trading venue: NYSE
- Sector / Industry: Health Care / Pharmaceuticals
- Index membership: S&P 500
